Skip to main content
Top
Published in: Pituitary 1/2015

01-02-2015

Central hypothyroidism in adults: better understanding for better care

Authors: Solange Grunenwald, Philippe Caron

Published in: Pituitary | Issue 1/2015

Login to get access

Abstract

Central hypothyroidism (CH) is a rare cause of hypothyroidism generally related to a hypothalamic–pituitary disorder or arising as an iatrogenic complication. In adults, CH may be secondary to quantitative and/or qualitative alterations in thyroid-stimulating hormone (TSH) secretion. The disease is difficult to diagnose clinically because it lacks specific clinical signs and these may be masked by other anterior pituitary hormone secretion deficiencies. In patients with long-standing and marked CH, a diagnosis may be made based on low free T4 levels and normal, low or moderately increased TSH levels. In patients with early-stage or moderate CH, exploration of the circadian TSH cycle, determination of TSH response after a TRH test or recombinant TSH injection, estimation of TSH index, or evaluation of peripheral indexes of thyroid hormone metabolism may be required to establish a diagnosis. Regarding treatment, patients should receive levothyroxine replacement therapy, but hormone objectives during follow-up need to be precisely determined in order to reduce cardiovascular risks and to improve the quality of life of patients.
Literature
2.
go back to reference Persani L (2012) Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 97:3068–3078PubMedCrossRef Persani L (2012) Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 97:3068–3078PubMedCrossRef
3.
go back to reference Tagami T, Kimura H, Ohtani S et al (2011) Multi-center study on the prevalence of hypothyroidism in patients with hypercholesterolemia. Endocr J 58:449–457PubMedCrossRef Tagami T, Kimura H, Ohtani S et al (2011) Multi-center study on the prevalence of hypothyroidism in patients with hypercholesterolemia. Endocr J 58:449–457PubMedCrossRef
4.
go back to reference Wardle CA, Fraser WD, Squire CR (2001) Pitfalls in the use of thyrotropin concentration as a first-line thyroid-function test. Lancet 357:1013–1014PubMedCrossRef Wardle CA, Fraser WD, Squire CR (2001) Pitfalls in the use of thyrotropin concentration as a first-line thyroid-function test. Lancet 357:1013–1014PubMedCrossRef
5.
go back to reference Sell MA, Schott M, Tharandt L et al (2008) Functional central hypothyroidism in the elderly. Aging Clin Exp Res 20:207–210PubMedCrossRef Sell MA, Schott M, Tharandt L et al (2008) Functional central hypothyroidism in the elderly. Aging Clin Exp Res 20:207–210PubMedCrossRef
6.
go back to reference Caron PJ, Nieman LK, Rose SR et al (1986) Deficient nocturnal surge of thyrotropin in central hypothyroidism. J Clin Endocrinol Metab 62:960–964PubMedCrossRef Caron PJ, Nieman LK, Rose SR et al (1986) Deficient nocturnal surge of thyrotropin in central hypothyroidism. J Clin Endocrinol Metab 62:960–964PubMedCrossRef
7.
go back to reference Rose SR, Manasco PK, Pearce S et al (1990) Hypothyroidism and deficiency of the nocturnal thyrotropin surge in children with hypothalamic–pituitary disorders. J Clin Endocrinol Metab 70:1750–1755PubMedCrossRef Rose SR, Manasco PK, Pearce S et al (1990) Hypothyroidism and deficiency of the nocturnal thyrotropin surge in children with hypothalamic–pituitary disorders. J Clin Endocrinol Metab 70:1750–1755PubMedCrossRef
8.
go back to reference Persani L (1998) Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Thyroid 8:941–946PubMedCrossRef Persani L (1998) Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Thyroid 8:941–946PubMedCrossRef
9.
go back to reference Horimoto M, Nishikawa M, Ishihara T et al (1995) Bioactivity of thyrotropin (TSH) in patients with central hypothyroidism: comparison between in vivo 3,5,3′-triiodothyronine response to TSH and in vitro bioactivity of TSH. J Clin Endocrinol Metab 80:1124–1128PubMed Horimoto M, Nishikawa M, Ishihara T et al (1995) Bioactivity of thyrotropin (TSH) in patients with central hypothyroidism: comparison between in vivo 3,5,3′-triiodothyronine response to TSH and in vitro bioactivity of TSH. J Clin Endocrinol Metab 80:1124–1128PubMed
10.
go back to reference Persani L, Ferretti E, Borgato S et al (2000) Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 85:3631–3635PubMed Persani L, Ferretti E, Borgato S et al (2000) Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 85:3631–3635PubMed
11.
go back to reference Beck-Peccoz P, Persani L (1994) Variable biological activity of thyroid-stimulating hormone. Eur J Endocrinol 131:331–340PubMedCrossRef Beck-Peccoz P, Persani L (1994) Variable biological activity of thyroid-stimulating hormone. Eur J Endocrinol 131:331–340PubMedCrossRef
12.
go back to reference Beck-Peccoz P, Amr S, Menezes-Ferreira MM et al (1985) Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med 312:1085–1090PubMedCrossRef Beck-Peccoz P, Amr S, Menezes-Ferreira MM et al (1985) Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. N Engl J Med 312:1085–1090PubMedCrossRef
13.
14.
go back to reference Bensing S, Hulting AL, Höög A, Ericson K, Kämpe O (2007) Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies. J Endocrinol Invest 30:153–162PubMedCrossRef Bensing S, Hulting AL, Höög A, Ericson K, Kämpe O (2007) Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies. J Endocrinol Invest 30:153–162PubMedCrossRef
15.
go back to reference Yamamoto M, Iguchi G, Takeno R et al (2011) Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans. J Clin Invest 121:113–119PubMedCentralPubMedCrossRef Yamamoto M, Iguchi G, Takeno R et al (2011) Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans. J Clin Invest 121:113–119PubMedCentralPubMedCrossRef
16.
go back to reference Juszczak A, Gupta A, Karavitaki N et al (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1–5PubMedCrossRef Juszczak A, Gupta A, Karavitaki N et al (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1–5PubMedCrossRef
17.
go back to reference Loeffler JS, Shih HA (2011) Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 96:1992–2003PubMedCrossRef Loeffler JS, Shih HA (2011) Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 96:1992–2003PubMedCrossRef
18.
go back to reference Littley MD, Shalet SM, Beardwell CG et al (1989) Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf) 31:363–373CrossRef Littley MD, Shalet SM, Beardwell CG et al (1989) Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf) 31:363–373CrossRef
19.
go back to reference Brabant G, Toogood AA, Shalet SM et al (2012) Hypothyroidism following childhood cancer therapy: an under-diagnosed complication. Int J Cancer 130:1145–1150PubMedCrossRef Brabant G, Toogood AA, Shalet SM et al (2012) Hypothyroidism following childhood cancer therapy: an under-diagnosed complication. Int J Cancer 130:1145–1150PubMedCrossRef
20.
go back to reference Kokshoorn NE, Wassenaar MJ, Biermasz NR et al (2010) Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. Eur J Endocrinol 162:11–18PubMedCrossRef Kokshoorn NE, Wassenaar MJ, Biermasz NR et al (2010) Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. Eur J Endocrinol 162:11–18PubMedCrossRef
21.
go back to reference Tanriverdi F, De Bellis A, Battaglia M et al (2010) Investigation of antihypothalamus and antipituitary antibodies in amateur boxers: is chronic repetitive head trauma-induced pituitary dysfunction associated with autoimmunity? Eur J Endocrinol 162:861–867PubMedCrossRef Tanriverdi F, De Bellis A, Battaglia M et al (2010) Investigation of antihypothalamus and antipituitary antibodies in amateur boxers: is chronic repetitive head trauma-induced pituitary dysfunction associated with autoimmunity? Eur J Endocrinol 162:861–867PubMedCrossRef
22.
go back to reference Daffara F, De Francia S, Reimondo G et al (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15:1043–1053PubMedCrossRef Daffara F, De Francia S, Reimondo G et al (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15:1043–1053PubMedCrossRef
23.
go back to reference Zatelli MC, Gentilin E, Daffara F et al (2010) Therapeutic concentrations of mitotane (o, p′-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151:2453–2461PubMedCrossRef Zatelli MC, Gentilin E, Daffara F et al (2010) Therapeutic concentrations of mitotane (o, p′-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151:2453–2461PubMedCrossRef
24.
go back to reference Sharma V, Hays WR, Wood WM et al (2006) Effects of rexinoids on thyrotrope function and the hypothalamic–pituitary–thyroid axis. Endocrinology 147:1438–1451PubMedCrossRef Sharma V, Hays WR, Wood WM et al (2006) Effects of rexinoids on thyrotrope function and the hypothalamic–pituitary–thyroid axis. Endocrinology 147:1438–1451PubMedCrossRef
26.
go back to reference Jorgensen JO, Moller J, Laursen T, Orskov H, Christiansen JS, Weeke J (1994) Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clin Endocrinol 41:609–614CrossRef Jorgensen JO, Moller J, Laursen T, Orskov H, Christiansen JS, Weeke J (1994) Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clin Endocrinol 41:609–614CrossRef
27.
go back to reference Agha A, Walker D, Perry L et al (2007) Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol 66:72–77 Agha A, Walker D, Perry L et al (2007) Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol 66:72–77
28.
go back to reference Vigersky RA, Filmore-Nassar A, Glass AR (2006) Thyrotropin suppression by metformin. J Clin Endocrinol Metab 91:225–227PubMedCrossRef Vigersky RA, Filmore-Nassar A, Glass AR (2006) Thyrotropin suppression by metformin. J Clin Endocrinol Metab 91:225–227PubMedCrossRef
29.
go back to reference Cappelli C, Rotondi M, Pirola I et al (2009) TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 32:1589–1590PubMedCentralPubMedCrossRef Cappelli C, Rotondi M, Pirola I et al (2009) TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 32:1589–1590PubMedCentralPubMedCrossRef
30.
go back to reference Cappelli C, Rotondi M, Pirola I et al (2012) Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 167:261–265PubMed Cappelli C, Rotondi M, Pirola I et al (2012) Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 167:261–265PubMed
31.
go back to reference Lupoli R, Di Minno A, Tortora A, Ambrosino P, Arianna Lupoli G, Di Minno MN (2014) Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab 99:E143–E148PubMedCrossRef Lupoli R, Di Minno A, Tortora A, Ambrosino P, Arianna Lupoli G, Di Minno MN (2014) Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab 99:E143–E148PubMedCrossRef
32.
go back to reference Lopez M, Varela L, Vasquez MJ et al (2010) Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16:1001–1008PubMedCentralPubMedCrossRef Lopez M, Varela L, Vasquez MJ et al (2010) Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16:1001–1008PubMedCentralPubMedCrossRef
33.
go back to reference Brenta G, Danzi S, Klein I (2007) Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 3:632–640PubMedCrossRef Brenta G, Danzi S, Klein I (2007) Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 3:632–640PubMedCrossRef
34.
go back to reference Alkemade A, Unmehopa UA, Wiersinga WM et al (2005) Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J Clin Endocrinol Metab 90:323–327PubMedCrossRef Alkemade A, Unmehopa UA, Wiersinga WM et al (2005) Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J Clin Endocrinol Metab 90:323–327PubMedCrossRef
35.
go back to reference Collu R, Tang J, Castagné J et al (1997) A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 82:1561–1565PubMed Collu R, Tang J, Castagné J et al (1997) A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 82:1561–1565PubMed
36.
go back to reference Bonomi M, Busnelli M, Beck-Peccoz P et al (2009) A family with complete resistance to thyrotropin-releasing hormone. N Engl J Med 360:731–734PubMedCrossRef Bonomi M, Busnelli M, Beck-Peccoz P et al (2009) A family with complete resistance to thyrotropin-releasing hormone. N Engl J Med 360:731–734PubMedCrossRef
37.
go back to reference Medeiros-Neto G, Herodotou DT, Rajan S et al (1996) A circulating, biologically inactive thyrotropin caused by a mutation in the beta subunit gene. J Clin Invest 97:1250–1256PubMedCentralPubMedCrossRef Medeiros-Neto G, Herodotou DT, Rajan S et al (1996) A circulating, biologically inactive thyrotropin caused by a mutation in the beta subunit gene. J Clin Invest 97:1250–1256PubMedCentralPubMedCrossRef
38.
go back to reference Brumm H, Pfeufer A, Biebermann H, Schnabel D, Deiss D, Grüters A (2002) Congenital central hypothyroidism due to homozygous thyrotropin beta 313 delta mutation is caused by a founder effect. J Clin Endocrinol Metab 87:4811–4816PubMedCrossRef Brumm H, Pfeufer A, Biebermann H, Schnabel D, Deiss D, Grüters A (2002) Congenital central hypothyroidism due to homozygous thyrotropin beta 313 delta mutation is caused by a founder effect. J Clin Endocrinol Metab 87:4811–4816PubMedCrossRef
39.
go back to reference Alatzoglou KS, Dattani MT (2009) Genetic forms of hypopituitarism and their manifestation in the neonatal period. Early Hum Dev 85:705–712PubMedCrossRef Alatzoglou KS, Dattani MT (2009) Genetic forms of hypopituitarism and their manifestation in the neonatal period. Early Hum Dev 85:705–712PubMedCrossRef
40.
go back to reference Sun Y, Bak B, Schoenmakers N et al (2012) Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet 44:1375–1381PubMedCentralPubMedCrossRef Sun Y, Bak B, Schoenmakers N et al (2012) Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet 44:1375–1381PubMedCentralPubMedCrossRef
41.
go back to reference Joustra SD, Schoenmakers N, Persani L et al (2013) The IGSF1 deficiency syndrome: characteristics of male and female patients. J Clin Endocrinol Metab 98:4942–4952PubMedCrossRef Joustra SD, Schoenmakers N, Persani L et al (2013) The IGSF1 deficiency syndrome: characteristics of male and female patients. J Clin Endocrinol Metab 98:4942–4952PubMedCrossRef
42.
go back to reference Alexopoulou O, Beguin C, De Nayer P et al (2004) Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 150:1–8PubMedCrossRef Alexopoulou O, Beguin C, De Nayer P et al (2004) Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 150:1–8PubMedCrossRef
43.
go back to reference Barbesino G, Sluss PM, Caturegli P (2012) Central hypothyroidism in a patient with pituitary autoimmunity: evidence for TSH-independent thyroid hormone synthesis. J Clin Endocrinol Metab 97:345–350PubMedCentralPubMedCrossRef Barbesino G, Sluss PM, Caturegli P (2012) Central hypothyroidism in a patient with pituitary autoimmunity: evidence for TSH-independent thyroid hormone synthesis. J Clin Endocrinol Metab 97:345–350PubMedCentralPubMedCrossRef
44.
go back to reference Ferretti E, Persani L, Jaffrain-Rea ML et al (1999) Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 84:924–929PubMed Ferretti E, Persani L, Jaffrain-Rea ML et al (1999) Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 84:924–929PubMed
45.
go back to reference Faglia G, Beck-Peccoz P, Ferrari C, Ambrosi B, Spada A, Travaglini P, Paracchi S (1973) Plasma thyrotropin response to thyrotropin-releasing hormone in patients with pituitary and hypothalamic disorders. J Clin Endocrinol Metab 37:595–601PubMedCrossRef Faglia G, Beck-Peccoz P, Ferrari C, Ambrosi B, Spada A, Travaglini P, Paracchi S (1973) Plasma thyrotropin response to thyrotropin-releasing hormone in patients with pituitary and hypothalamic disorders. J Clin Endocrinol Metab 37:595–601PubMedCrossRef
46.
go back to reference Yamakita N, Komaki T, Takao T et al (2001) Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion. J Clin Endocrinol Metab 86:1054–1060PubMedCrossRef Yamakita N, Komaki T, Takao T et al (2001) Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion. J Clin Endocrinol Metab 86:1054–1060PubMedCrossRef
47.
go back to reference Jostel A, Rydert WD, Shalet SM (2009) The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH index. Clin Endocrinol 71:529–534CrossRef Jostel A, Rydert WD, Shalet SM (2009) The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH index. Clin Endocrinol 71:529–534CrossRef
48.
go back to reference Filipsson H, Nystrom E, Johannsson G (2008) Exploring the use of recombinant human TSH in the diagnosis of central hypothyroidism. Eur J Endocrinol 159:153–160PubMedCrossRef Filipsson H, Nystrom E, Johannsson G (2008) Exploring the use of recombinant human TSH in the diagnosis of central hypothyroidism. Eur J Endocrinol 159:153–160PubMedCrossRef
49.
go back to reference Doin FC, Rosa-Borges M, Martins MR et al (2012) Diagnosis of subclinical central hypothyroidism in patients with hypothalamic–pituitary disease by Doppler echocardiography. Eur J Endocrinol 166:631–640PubMedCrossRef Doin FC, Rosa-Borges M, Martins MR et al (2012) Diagnosis of subclinical central hypothyroidism in patients with hypothalamic–pituitary disease by Doppler echocardiography. Eur J Endocrinol 166:631–640PubMedCrossRef
50.
go back to reference Klose M, Marina D, Hartoft-Nielsen ML et al (2013) Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. J Clin Endocrinol Metab 98:3802–3810PubMedCrossRef Klose M, Marina D, Hartoft-Nielsen ML et al (2013) Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. J Clin Endocrinol Metab 98:3802–3810PubMedCrossRef
51.
go back to reference Slawik M, Klawitter B, Meiser E et al (2007) Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 92:4115–4122PubMedCrossRef Slawik M, Klawitter B, Meiser E et al (2007) Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 92:4115–4122PubMedCrossRef
52.
go back to reference Koulouri O, Auldin MA, Agarwal R et al (2011) Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf) 74:744–749CrossRef Koulouri O, Auldin MA, Agarwal R et al (2011) Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf) 74:744–749CrossRef
53.
go back to reference Beck-Peccoz P (2011) Treatment of central hypothyroidism. Clin Endocrinol 74:671–672CrossRef Beck-Peccoz P (2011) Treatment of central hypothyroidism. Clin Endocrinol 74:671–672CrossRef
54.
go back to reference Shimon I, Cohen O, Lubetsky A et al (2002) Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 12:823–827PubMedCrossRef Shimon I, Cohen O, Lubetsky A et al (2002) Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 12:823–827PubMedCrossRef
55.
go back to reference Carrozza V, Csako G, Yanovski JA et al (1999) Levothyroxine replacement therapy in central hypothyroidism: a practice report. Pharmacotherapy 19:349–355PubMedCrossRef Carrozza V, Csako G, Yanovski JA et al (1999) Levothyroxine replacement therapy in central hypothyroidism: a practice report. Pharmacotherapy 19:349–355PubMedCrossRef
56.
go back to reference Porretti S, Giavoli C, Ronchi C et al (2002) Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T4 therapy become mandatory? J Clin Endocrinol Metab 87:2042–2045PubMedCrossRef Porretti S, Giavoli C, Ronchi C et al (2002) Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T4 therapy become mandatory? J Clin Endocrinol Metab 87:2042–2045PubMedCrossRef
57.
go back to reference Arafah BM (2001) Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 344:1743–1749PubMedCrossRef Arafah BM (2001) Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 344:1743–1749PubMedCrossRef
Metadata
Title
Central hypothyroidism in adults: better understanding for better care
Authors
Solange Grunenwald
Philippe Caron
Publication date
01-02-2015
Publisher
Springer US
Published in
Pituitary / Issue 1/2015
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-014-0559-8

Other articles of this Issue 1/2015

Pituitary 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.